A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin.
The Journal of investigative dermatology.
Times cited: 1
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
The Journal of clinical investigation.
Times cited: 51
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
Arthritis care & research.
Times cited: 34
- A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis and Rheumatism. 2008 Academic Article GET IT